The University of Chicago Header Logo

Connection

Stephen Hanauer to Anti-Inflammatory Agents, Non-Steroidal

Back to Details
This is a "connection" page, showing publications Stephen Hanauer has written about Anti-Inflammatory Agents, Non-Steroidal.
Stephen Hanauer
Connection Strength
7.256
Anti-Inflammatory Agents, Non-Steroidal
  1. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2016 Jul 03; 7:CD008870.
    View in: PubMed
    Score: 0.483
  2. Can we treat ulcerative colitis with nutritional supplements? Aliment Pharmacol Ther. 2012 Feb; 35(4):485; author reply 486-7.
    View in: PubMed
    Score: 0.356
  3. Update on the management of ulcerative colitis. Curr Gastroenterol Rep. 2011 Oct; 13(5):475-85.
    View in: PubMed
    Score: 0.347
  4. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2010 Dec 08; (12):CD008870.
    View in: PubMed
    Score: 0.328
  5. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009 Dec; 137(6):1934-43.e1-3.
    View in: PubMed
    Score: 0.302
  6. Mea culpa. Nat Clin Pract Gastroenterol Hepatol. 2008 Aug; 5(8):409.
    View in: PubMed
    Score: 0.279
  7. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther. 2008 Mar; 27 Suppl 1:15-21.
    View in: PubMed
    Score: 0.271
  8. Semantics. Nat Clin Pract Gastroenterol Hepatol. 2008 Feb; 5(2):59.
    View in: PubMed
    Score: 0.270
  9. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol. 2007 Dec; 21(12):827-34.
    View in: PubMed
    Score: 0.266
  10. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther. 2006 Oct; 24 Suppl 3:37-40.
    View in: PubMed
    Score: 0.246
  11. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov; 100(11):2478-85.
    View in: PubMed
    Score: 0.231
  12. The case for using 5-aminosalicyclates in Crohn's disease: pro. Inflamm Bowel Dis. 2005 Jun; 11(6):609-12.
    View in: PubMed
    Score: 0.224
  13. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):373-84.
    View in: PubMed
    Score: 0.220
  14. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004 Sep; 127(3):723-9.
    View in: PubMed
    Score: 0.213
  15. Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterol Clin North Am. 2004 Jun; 33(2):303-17, ix-x.
    View in: PubMed
    Score: 0.209
  16. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004 May; 2(5):379-88.
    View in: PubMed
    Score: 0.208
  17. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003 Jan; 17(1):29-42.
    View in: PubMed
    Score: 0.189
  18. Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis. Am J Gastroenterol. 2003 Jan; 98(1):215-6.
    View in: PubMed
    Score: 0.189
  19. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003 Jan; 114(1):39-43.
    View in: PubMed
    Score: 0.189
  20. Review article: drug-induced small bowel injury. Aliment Pharmacol Ther. 2021 12; 54(11-12):1370-1388.
    View in: PubMed
    Score: 0.174
  21. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001 Oct; 96(10):2929-33.
    View in: PubMed
    Score: 0.174
  22. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000 Nov; 23(5):429-48.
    View in: PubMed
    Score: 0.163
  23. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol. 2000 Jul; 95(7):1749-54.
    View in: PubMed
    Score: 0.159
  24. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020 02; 115(2):202-210.
    View in: PubMed
    Score: 0.155
  25. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999 Dec; 117(6):1271-7.
    View in: PubMed
    Score: 0.153
  26. Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis. Gut. 1999 Apr; 44(4):455.
    View in: PubMed
    Score: 0.146
  27. Too Soon to Discard 5-ASAs? Am J Gastroenterol. 2019 03; 114(3):534-535.
    View in: PubMed
    Score: 0.145
  28. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis. 1998 May; 4(2):79-83.
    View in: PubMed
    Score: 0.137
  29. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Aliment Pharmacol Ther. 2011 Oct; 34(7):747-56.
    View in: PubMed
    Score: 0.086
  30. 5-ASA enema therapy. Neth J Med. 1989 Jun; 35 Suppl 1:S11-20.
    View in: PubMed
    Score: 0.074
  31. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. 2008 Jan 21; 14(3):354-77.
    View in: PubMed
    Score: 0.067
  32. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. Inflamm Bowel Dis. 2005 Mar; 11(3):253-7.
    View in: PubMed
    Score: 0.055
  33. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther. 2004 May 15; 19(10):1089-98.
    View in: PubMed
    Score: 0.052
  34. Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(3):104-17.
    View in: PubMed
    Score: 0.051
  35. Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt. Am J Gastroenterol. 2003 Mar; 98(3):697-8.
    View in: PubMed
    Score: 0.048
  36. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther. 2002 Jan; 16(1):87-99.
    View in: PubMed
    Score: 0.044
  37. Evolving treatment strategies for inflammatory bowel disease. Annu Rev Med. 2001; 52:299-318.
    View in: PubMed
    Score: 0.041
  38. Update on medical management of inflammatory bowel disease: ulcerative colitis. Rev Gastroenterol Disord. 2001; 1(4):169-76.
    View in: PubMed
    Score: 0.041
  39. Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. J Crohns Colitis. 2020 Sep 16; 14(9):1274-1281.
    View in: PubMed
    Score: 0.040
  40. Medical therapy to reduce postoperative Crohn's disease recurrence. Am J Gastroenterol. 2000 May; 95(5):1139-46.
    View in: PubMed
    Score: 0.039
  41. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000 May; 95(5):1263-76.
    View in: PubMed
    Score: 0.039
  42. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May; 5(2):119-33.
    View in: PubMed
    Score: 0.037
  43. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci. 1995 May; 40(5):931-5.
    View in: PubMed
    Score: 0.028
  44. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci. 1995 Feb; 40(2):296-304.
    View in: PubMed
    Score: 0.027
  45. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26.
    View in: PubMed
    Score: 0.021
  46. Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease experts. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S11-21.
    View in: PubMed
    Score: 0.013
  47. Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S2-10.
    View in: PubMed
    Score: 0.013
  48. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002 Feb; 122(2):512-30.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.